GLP-1 Receptor Agonists and Perimenopause: Weight, Metabolic Health, and What the Evidence Shows

Why Perimenopause Is a Metabolic Turning Point

The hormonal shift that begins years before the last menstrual period does far more than cause hot flashes. Falling estradiol levels alter how the body stores fat, responds to insulin, and regulates appetite. The result is a predictable cluster of changes: visceral fat replaces subcutaneous fat, fasting insulin climbs, and triglycerides rise, often without any change in caloric intake or physical activity. For women who already carry metabolic risk factors, including PCOS, prediabetes, or a family history of type 2 diabetes, the perimenopausal transition can accelerate a process that was already underway.

Estrogen acts on estrogen receptor alpha in the hypothalamus to suppress food intake and on skeletal muscle to upregulate GLUT4, the transporter that moves glucose into cells. When estradiol drops, both effects weaken simultaneously. A 2019 analysis in Climacteric documented a measurable decline in whole-body insulin sensitivity beginning in the late reproductive stage, two to three years before menopause, independent of body-mass index. [1]

Women also report a qualitative shift in hunger and satiety during perimenopause. That subjective experience has a biological basis. GLP-1, the gut-derived hormone that tells the brain to stop eating, is released from intestinal L-cells partly in response to estrogen signaling. As estrogen falls, endogenous GLP-1 secretion may decrease, widening the gap between appetite and energy need. Pharmacological GLP-1 receptor agonists close that gap by binding the same receptor with sustained, high-affinity activation.

How GLP-1 Receptor Agonists Work in the Context of Hormonal Change

GLP-1 receptor agonists mimic glucagon-like peptide-1, a peptide released by the gut after eating. They slow gastric emptying, signal satiety to the hypothalamus, and stimulate glucose-dependent insulin secretion while suppressing glucagon. None of those mechanisms depend on ovarian estrogen, which is exactly why they remain effective across the menopausal transition.

The two agents with the strongest weight-loss evidence are semaglutide (Wegovy, 2.4 mg subcutaneous weekly) and tirzepatide (Zepbound, 5 to 15 mg subcutaneous weekly). Tirzepatide adds a glucose-dependent insulinotropic polypeptide (GIP) agonist action on top of GLP-1 receptor activation, which may explain why its weight-loss effect is larger. The FDA approved Wegovy in 2021 for adults with a BMI of 30 or above, or BMI <27 with at least one weight-related condition, and approved Zepbound in 2023 under the same criteria. [2][3]

Neither label specifies a minimum or maximum age, and neither excludes perimenopausal or postmenopausal women. Prescribers at HealthRX evaluate candidates using the standard BMI and comorbidity criteria plus a full hormonal and metabolic panel, because baseline insulin, fasting glucose, lipids, and estradiol all affect how aggressively to initiate treatment.

The Weight-Loss Data: What Women in This Age Group Can Expect

STEP-1 (N=1,961) randomized adults with a BMI of 30 or above, or BMI <27 with a weight-related comorbidity, to subcutaneous semaglutide 2.4 mg or placebo once weekly for 68 weeks. Participants on semaglutide lost a mean of 14.9% of body weight versus 2.4% with placebo (P<0.001). [4] The trial did not report a perimenopausal subgroup separately, but the mean age was 46 years and roughly 74% of participants were women, making the population broadly representative of the perimenopausal cohort.

STEP-5 extended semaglutide treatment to 104 weeks in adults without diabetes. Mean weight loss at two years was 15.2%, compared with 2.6% for placebo, confirming that the effect is durable rather than transient. [5] Weight regain after discontinuation is real, which is why the HealthRX protocol frames GLP-1 therapy as a long-term intervention rather than a short course.

Tirzepatide produced even larger reductions in SURMOUNT-1 (N=2,539), where the 15 mg dose achieved a mean weight loss of 22.5% at 72 weeks versus 2.4% for placebo (P<0.001). [6] SURMOUNT-3 showed that patients who completed a 12-week intensive lifestyle lead-in and then started tirzepatide lost an additional 18.4% of body weight over 72 weeks, for a combined 26.1% total reduction from pre-lead-in weight. [7]

In absolute terms, a perimenopausal woman at 90 kg who achieves 15% weight loss eliminates roughly 13.5 kg, much of it visceral adipose tissue. That level of visceral fat reduction translates directly into lower fasting insulin, lower triglycerides, and reduced inflammatory markers, all of which are elevated during the menopausal transition. A 2022 sub-analysis of STEP trial data published in Diabetes Care found that semaglutide reduced visceral adipose tissue area by a mean of 30.5% compared with 6.4% for placebo, specifically outpacing total body-weight loss. [8]

GLP-1 Therapy for Perimenopausal Women with Prediabetes

Perimenopause and prediabetes are not coincidental co-occurrences. The same insulin resistance that accumulates during the menopausal transition is the substrate for prediabetes, defined as fasting glucose of 100 to 125 mg/dL or HbA1c of 5.7 to 6.4%.

STEP-5 data showed that among participants with prediabetes at baseline, approximately 84% returned to normoglycemia after 104 weeks of semaglutide, compared with 48% on placebo. More relevant for primenopausal clinical decision-making: only 1.6% of the semaglutide group progressed to type 2 diabetes over two years, versus 6.9% in the placebo group. [5] That is roughly an 80% relative risk reduction.

The American Diabetes Association's 2024 Standards of Care note that GLP-1 receptor agonists with proven cardiovascular benefit should be considered in patients with type 2 diabetes and established cardiovascular disease, or those at high cardiovascular risk, independent of glycemic control. [9] Perimenopausal women, who are transitioning from the cardioprotective estrogen environment of the reproductive years into the higher-risk postmenopausal state, qualify as a population where early metabolic intervention carries long-term cardiovascular dividend.

The American Association of Clinical Endocrinologists (AACE) obesity guidelines state: "Pharmacotherapy is recommended as an adjunct to lifestyle therapy for patients who have not achieved or are not expected to achieve clinically meaningful weight loss with lifestyle therapy alone." [10] A perimenopausal woman with BMI 28, prediabetes, and a first-degree relative with type 2 diabetes meets that threshold directly.

GLP-1 Therapy for Women with Type 2 Diabetes Diagnosed During Perimenopause

Type 2 diabetes diagnosed in the perimenopausal window carries a different risk profile than diabetes diagnosed at 30. Cardiovascular risk is already rising as estrogen protection wanes, and glycemic variability tends to be higher because of the hormonal fluctuation.

STEP-2 (N=1,210) enrolled adults with type 2 diabetes and a BMI of 27 or above and found that semaglutide 2.4 mg produced 9.6% mean weight loss and a 1.6 percentage-point reduction in HbA1c over 68 weeks, compared with 3.4% weight loss and 0.4 percentage-point HbA1c reduction for placebo (P<0.001 for both). [11]

SURMOUNT-2 tested tirzepatide in adults with type 2 diabetes and BMI of 27 or above. The 15 mg dose produced a mean weight loss of 15.7% at 72 weeks and reduced HbA1c by 2.58 percentage points from a mean baseline of 8.02%, compared with 3.3% weight loss and 0.97-point HbA1c reduction for placebo. [12]

The SELECT cardiovascular outcomes trial (N=17,604) enrolled adults with overweight or obesity and established cardiovascular disease but without diabetes. Semaglutide 2.4 mg reduced the rate of major adverse cardiovascular events (MACE) by 20% compared with placebo over a mean follow-up of 34.2 months (HR 0.80 to 95% CI 0.72 to 0.90, P<0.001). [13] While the trial excluded patients with diabetes, the cardiovascular signal reinforces the rationale for early intervention in perimenopausal women whose cardiometabolic risk is rising.

PCOS, Perimenopause, and GLP-1: A Frequently Missed Connection

Polycystic ovary syndrome does not resolve at menopause. Women with PCOS carry elevated androgen levels, insulin resistance, and a higher lifetime prevalence of type 2 diabetes into and through the menopausal transition. Their perimenopausal metabolic burden is compounded rather than resolved.

GLP-1 receptor agonists reduce androgen levels in women with PCOS through two pathways. First, weight loss itself reduces ovarian and adrenal androgen production. Second, lower insulin levels reduce luteinizing hormone pulsatility and the subsequent ovarian theca-cell androgen synthesis. A 2023 meta-analysis in Frontiers in Endocrinology covering 13 randomized controlled trials (N=529) found that GLP-1 agonist therapy reduced free androgen index by a mean of 1.64 units and fasting insulin by 2.37 mIU/L compared with control, with semaglutide and liraglutide showing the largest effects. [14]

For perimenopausal women with PCOS who are still experiencing irregular cycles, the insulin-lowering and androgen-lowering effects may partially restore cycle regularity, which has implications for contraceptive counseling. Pregnancy remains possible during perimenopause, and all GLP-1 receptor agonists carry a Pregnancy Category X-equivalent recommendation to discontinue at least two months before a planned conception.

GLP-1 Medications and Weight Loss in Men: What Changes

Men are included in this article because perimenopausal households often include male partners with their own metabolic concerns, and because patient questions about GLP-1 therapy frequently span both sexes. Men do not experience estrogen-driven visceral fat redistribution the same way, but they develop their own testosterone-related metabolic changes from the mid-40s onward.

In STEP-1, men lost slightly more absolute weight than women on semaglutide (mean 15.8% vs. 14.5%), but the difference was not statistically significant. In SURMOUNT-1, male participants on tirzepatide 15 mg lost a mean of 23.1% versus 21.8% for women, again without a statistically significant sex interaction. [6] Both sexes show clinically meaningful visceral fat reduction, HbA1c improvement, and blood pressure reduction.

Men with hypogonadism and obesity present a specific consideration. Low testosterone promotes visceral fat accumulation, and visceral fat in turn aromatizes testosterone to estrogen, further suppressing the hypothalamic-pituitary-testicular axis. GLP-1-mediated weight loss breaks part of that cycle. A 2023 retrospective analysis in Obesity found that men who lost 10% or more of body weight with GLP-1 therapy showed a mean 4.1 nmol/L increase in total testosterone at 12 months, independent of TRT. [15]

Practical Prescribing: Dosing, Side Effects, and Monitoring During Perimenopause

Both semaglutide and tirzepatide use a slow dose-escalation schedule designed to minimize nausea and vomiting. The Wegovy label specifies a four-step titration from 0.25 mg weekly to the 2.4 mg maintenance dose over 16 weeks. The Zepbound label uses a similar stepwise increase from 2.5 mg to a target of 5, 10, or 15 mg depending on tolerability. [2][3]

Nausea affects roughly 44% of patients on semaglutide 2.4 mg and 31% on placebo in STEP-1, with the majority of events occurring during titration and resolving by week 20. [4] Small, low-fat meals, adequate hydration, and avoiding the injection on an empty stomach reduce severity. Perimenopausal women who are also experiencing nausea from hormonal fluctuation may find the early titration weeks more difficult and may benefit from a slower-than-label titration pace.

Monitoring during the first six months should include fasting glucose and HbA1c, a basic metabolic panel, lipids, and blood pressure at baseline and at 12 and 24 weeks. Women on concurrent hormone therapy, specifically estradiol and progesterone, should be aware that gastric-emptying slowing caused by GLP-1 agonists may affect oral hormone absorption timing. Transdermal estradiol is not subject to this interaction, making it the preferred delivery route in women who start a GLP-1 agent while on HRT.

Contraindications include a personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2, and active pancreatitis. The FDA label for both Wegovy and Zepbound carries a boxed warning for thyroid C-cell tumors based on rodent data, though the clinical relevance in humans remains under investigation. [2][3]

Combining GLP-1 Therapy with Hormone Therapy

Hormone therapy (HRT) and GLP-1 receptor agonists address different but complementary aspects of perimenopausal metabolic change. HRT, particularly systemic estradiol, reduces vasomotor symptoms, maintains bone density, and partially mitigates the insulin resistance that follows estrogen withdrawal. GLP-1 agonists target appetite, gastric emptying, and glucose-dependent insulin secretion.

The two classes are not contraindicated together, and there is a mechanistic rationale for combination use. A 2021 observational study in Menopause found that women on systemic HRT had 19% lower fasting insulin and 11% lower waist circumference at five years than those not on HRT, after adjusting for baseline BMI. [16] Adding a GLP-1 agonist to this background may produce additive metabolic benefit, though no randomized head-to-head comparison of HRT alone, GLP-1 alone, and combined therapy in perimenopausal women has been published as of January 2025. HealthRX medical directors consider combination therapy on an individual basis, weighing HRT candidacy (contraindications include active breast cancer and certain thromboembolic conditions) against the metabolic risk burden.

The Menopause Society's 2022 position statement notes: "Hormone therapy remains the most effective treatment for vasomotor symptoms and has been shown to prevent bone loss and fracture." [17] That benefit does not overlap with GLP-1 effects, reinforcing that the two treatment categories serve different primary indications and can often coexist.

What to Expect at a HealthRX Perimenopause and GLP-1 Consultation

A HealthRX evaluation for a perimenopausal woman requesting GLP-1 therapy includes a structured medical history covering menstrual cycle changes over the past 12 months, current and prior HRT use, personal and family history of thyroid disease or endocrine tumors, PCOS history, prior gestational diabetes, current medications including any oral contraceptives, and prior weight-loss interventions. Laboratory prerequisites before prescribing include fasting glucose, HbA1c, lipid panel, thyroid-stimulating hormone, LH, FSH, and estradiol, with FSH above 10 IU/L on two measurements 4 to 6 weeks apart serving as one confirmatory marker of perimenopausal status per ACOG guidance. [18]

Women with a BMI of 30 or above, or BMI of 27 or above with prediabetes, type 2 diabetes, hypertension, or dyslipidemia, qualify for pharmacotherapy under FDA-approved indications. [2][3] Women with BMI <27 and isolated insulin resistance or PCOS may be candidates for off-label use, which requires documented informed consent and a clinical rationale recorded in the chart.

Monthly follow-up during the first four months, then quarterly, is the HealthRX standard. Weight, blood pressure, and self-reported side effects are reviewed at every visit. HbA1c is rechecked at three and six months in patients with diabetes or prediabetes. A two-percentage-point HbA1c reduction or a 5% weight reduction at 12 weeks is the HealthRX threshold for continuing therapy; failure to meet either benchmark prompts a review of adherence, diet, and whether dose escalation is appropriate.